Literature DB >> 28007985

Dose-Response Relationship between Inorganic Arsenic Exposure and Lung Cancer among Arseniasis Residents with Low Methylation Capacity.

Kuang-Hung Hsu1,2, Ke-Hung Tsui2, Ling-I Hsu3, Hung-Yi Chiou4, Chien-Jen Chen5.   

Abstract

Background: Exposure to inorganic arsenic (InAs) has been documented as a risk factor for lung cancer. This study examined the association between InAs exposure, its metabolism, and lung cancer occurrence.
Methods: We followed 1,300 residents from an arseniasis area in Taiwan, determined urinary InAs metabolites, and identified 39 lung cancer cases. Cox proportional hazards model was performed.
Results: The results demonstrated that participants with either the primary methylation index [monomethylarsonic acid (MMA)/InAs] or the secondary methylation index [dimethylarsenic acid (DMA)/MMA] lower than their respective median values were at a higher risk of lung cancer (HRs from 3.41 to 4.66) than those with high methylation capacity. The incidence density of lung cancer increased from 79.9/100,000 (year-1) to 467.4/100,000 (year-1) for residents with low methylation capacity and from 0 to 158.5/100,000 (year-1) for residents with high methylation capacity when the arsenic exposure dose increased from 2 to 10 ppb to ≥200 ppb, respectively. The analyses revealed a dose-response relationship between lung cancer occurrence and increasing arsenic concentrations in drinking water as well as cumulative arsenic exposure (monotonic trend test; P < 0.05 and P < 0.05, respectively) among the residents with low methylation capacity. The relationship between arsenic exposure and lung cancer among high methylators was not statistically significant.Conclusions: Hypomethylation responses to InAs exposure may dose dependently increase lung cancer occurrence.Impact: The high-risk characteristics observed among those exposed should be considered in future preventive medicine and research on arsenic carcinogenesis. Cancer Epidemiol Biomarkers Prev; 26(5); 756-61. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28007985     DOI: 10.1158/1055-9965.EPI-16-0281

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  5 in total

1.  Inactivation of miR-100 combined with arsenic treatment enhances the malignant transformation of BEAS-2B cells via stimulating epithelial -mesenchymal transition.

Authors:  Jia Yang; Zhijun Chen; Xinyi Wang; Mo Xu; Haoshu Fang; Feifei Li; Yakun Liu; Yu Jiang; Yi Ding; Juan Li; Siying Wang
Journal:  Cancer Biol Ther       Date:  2017-11-20       Impact factor: 4.742

2.  Joint effects of genomic markers and urinary methylation capacity associated with inorganic arsenic metabolism on the occurrence of cancers among residents in arseniasis-endemic areas: A cohort subset with average fifteen-year follow-up.

Authors:  Pei-Ju Liao; Kuang-Hung Hsu; Hung-Yi Chiou; Chien-Jen Chen; Chih-Hung Lee
Journal:  Biomed J       Date:  2020-10-13       Impact factor: 7.892

3.  Mendelian randomization analysis of arsenic metabolism and pulmonary function within the Hispanic Community Health Study/Study of Latinos.

Authors:  Molly Scannell Bryan; Tamar Sofer; Majid Afshar; Yasmin Mossavar-Rahmani; H Dean Hosgood; Naresh M Punjabi; Donglin Zeng; Martha L Daviglus; Maria Argos
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

4.  The best protection is early detection: Fostering timely and accurate screening.

Authors:  Aila Akosua Kattner
Journal:  Biomed J       Date:  2022-01-15       Impact factor: 7.892

5.  Low-Level Exposure to Arsenic in Drinking Water and Risk of Lung and Bladder Cancer: A Systematic Review and Dose-Response Meta-Analysis.

Authors:  Paolo Boffetta; Claire Borron
Journal:  Dose Response       Date:  2019-07-22       Impact factor: 2.658

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.